INNOVATIVE RESEARCH AND PRODUCTION PHARMACEUTICAL CLUSTER TASHKENT PHARMA PARK (PHASE 1)
Operator/initiator: Pharmaceutical Industry Development Agency of the Republic of Uzbekistan
Location: Tashkent region, Zangiatinsky district, Uzbekistan
Stage: July 2021 – the main parameters of the feasibility study were set
Dates: Commissioning is expected in November 2024
Investment amount: 130,2 million US dollars
The project is developed to incentivise integrated development of the pharmaceutical industry in the Republic, including through expansion of product portfolio of medical preparations, R&D, and personnel training in accordance with international educative standards.
The project is financed through EDCG funds Eximbank of Korea, UFRD, support and development of the pharmaceutical industry and direct foreign investment. The modular structure of the cluster with a total area of 50 ha implies establishment of industrial, academic, R&D, clinical and pre-clinical sectors.
On the territory of the cluster there will be production sites to produce innovative medical devices and equipment, multi-functional research university and its components, R&D centres, public expertise centre for pharmaceutical products, a datacentre, and other required infrastructure.
PRODUCTION OF SUBSTANCES AND MEDICAL PREPARATIONS IN THE FORM OF PILLS, CAPSULES, INJECTIONS (3 PHASES)
Operator/initiator: Cadila Pharmaceuticals Uzbekistan
Location: Andizhan region, Uzbekistan
Dates: Commissioning:
phase 1 – November 2023;
phase 2 – October 2024;
phase 3 – November 2024
Investment amount: 50 million US dollars
The Indian Cadila Pharmaceuticals Ltd. concluded an investment agreement with the Ministry of Investment and Foreign Trade of Uzbekistan on establishment of a pharmaceutical plants in the free economic zone named Andizhan-farm.
It is planned to attract direct foreign investment in 2020‑2025 valued at $50m with at least $10m to be allocated in 2020‑2021 to develop phase 1 of the project; to generate 400 new job opportunities; establishment of a modern system for pharmaceuticals production and quality management in line with international standards.
30 items of drugs and medical devices will be registered on an expedited basis with no fee charging for registration certificate.
PRODUCTION OF MEDICAL PREPARATIONS IN THE FORM OF PILLS AND CAPSULES
Operator/initiator: Solyphar Laboratories
Location: Tashkent region, Bostanlyk district, Uzbekistan
Dates: Commissioning is expected in November 2023
Investment amount: Over 20 million US dollars
In the Bostanlyk district of the Tashkent region it is expected to launch the construction of a factory to produce medical preparations valued at 20 million US dollars. It is expected that annual production capacity will be 500 million pills, 200 million capsules, 10 million sachets (powder). It is planned to release over 120 types of medical preparations. Solyphar is one of the leading players on the pharmaceutical market of Egypt which is also engaged in international collaborations.
The project implies construction of a pharmaceutical factory in the free economic zone territory located in the Bostanlyk district of the Tashkent region. This convenient location is provided with all the required infrastructure enabling to cut expenses on logistics and resource provision. This Uzbekistan’s project is the first large project which involves direct investment by Solyphar abroad. This new production will comply with the requirements of the proper production practice – GMP. To ensure high quality of products Solyphar is active in cooperating with the German International Quality Consulting (IQC) Group.
PRODUCTION OF MEDICAL PREPARATIONS TO CURE DIABETES
Operator/initiator: Multi Fruite Korea
Location: Samarkand region, Samarkand district, Uzbekistan
Dates: Commissioning is expected in November 2024
Investment amount: 20 million US dollars
Projected nameplate capacity is 275 tonnes. The project is expected to generate 150 job opportunities.
PRODUCTION OF SOLID MEDICAL PREPARATIONS AND CARBAPENEMS
Operator/initiator: Belpharm
Location: Tashkent, Unusabad district, Uzbekistan
Dates: Commissioning is expected in November 2024
Investment amount: 10 million US dollars
Within the framework of agreements with the Uzbekistan’s government in September 2018, there was a decision made on construction of a modern pharmaceutical plant in association with
foreign investors.
The plant will comply with the requirements of the international GMP standard. The company named Belpharm was established in January 2019 and started the development of that project in
October 2019.
Projected launch of Phase 1 is Q1 2021; Phase 2 – Q1 2024.
PRODUCTION OF MEDICAL PRODUCTS (MEDICAL GAUZES AND BANDAGES)
Operator/initiator: Radiks
Location: Tashkent region, Bostanlyk district, Uzbekistan
Dates: Commissioning is expected in November 2023
Investment amount: 7,70 million US dollars
Projected nameplate capacity is 25 million pcs. The project is expected to generate 30 job opportunities.
